Immunovant, Inc. reports recurring developments from a clinical-stage immunology business focused on anti-FcRn therapies for autoimmune diseases. Its news flow centers on IMVT-1402, a potential neonatal Fc receptor inhibitor, and batoclimab, with updates across Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, difficult-to-treat rheumatoid arthritis, Sjögren’s disease, cutaneous lupus erythematosus and thyroid eye disease.
Company updates also cover quarterly operating results, research and development spending, trial design and clinical-study results, safety observations, cash runway, financing activity and shareholder voting matters. Because Immunovant operates in a single research, development and manufacturing segment, recurring disclosures are closely tied to clinical execution, product-candidate manufacturing and capital resources for autoimmune disease programs.
Immunovant, focused on autoimmune diseases, reported its financial results for Q1 fiscal 2022, ending June 30, 2022. Key updates include the initiation of a pivotal trial for batoclimab in Myasthenia Gravis, with top-line data expected in 2024. Two pivotal trials for Thyroid Eye Disease are planned for the second half of 2022. Financially, the company incurred $31 million in cash payments due to clinical trial costs. The cash balance stood at $427 million, anticipated to last into 2025. Net loss was $40.4 million, reflecting increased R&D and G&A expenses.
Immunovant (Nasdaq: IMVT) plans to start two Phase 3 trials for batoclimab in thyroid eye disease (TED) by late 2022, with top-line results expected in the first half of 2025. The U.S. TED patient market is estimated at 8,000-18,000. The company has a cash balance of $494 million as of March 31, 2022, ensuring operational funding into 2025. R&D expenses surged to $32 million in Q4 2022, while FY 2022 losses grew to $156.7 million. The firm is also set to initiate a Phase 3 trial in myasthenia gravis (MG) by June 2022.
Immunovant, Inc. (Nasdaq: IMVT) will release its fourth quarter and full-year 2022 financial results on June 8, 2022, before U.S. market open. The company will also host a conference call and webcast at 8:00 AM ET the same day, featuring a question-and-answer session for investors. Immunovant focuses on therapies for autoimmune diseases, particularly its investigational compound, batoclimab, a monoclonal antibody targeting the neonatal Fc receptor (FcRn). This information can be accessed via their investor relations website.
Immunovant (Nasdaq: IMVT) announced on May 23, 2022, that CEO Pete Salzmann will participate in a fireside chat at the H.C. Wainwright Global Investment Conference from May 23-26, 2022.
The chat is scheduled for May 25 at 12:30 pm ET and will be available via webcast on the company's Investor Relations page at www.immunovant.com.
Immunovant focuses on developing innovative therapies for autoimmune diseases, notably their investigational compound, batoclimab.
Immunovant (Nasdaq: IMVT) announced that CEO Pete Salzmann will participate in a fireside chat at the UBS Global Healthcare Conference from May 23-25, 2022.
The chat is scheduled for May 23 at 1:15 PM ET and will be accessible via webcast on the company's website. Immunovant is dedicated to developing therapies for autoimmune diseases, focusing on its investigational compound, batoclimab, a fully human monoclonal antibody targeting the neonatal Fc receptor.
Immunovant (Nasdaq: IMVT) announced that CEO Pete Salzmann, M.D., will participate in a fireside chat during the LifeSci Partners’ virtual Immunology and Inflammation Symposium on May 10-11, 2022. The chat is scheduled for 12:00 PM Eastern Time on May 10. Interested parties can access the webcast through the Investor Relations section of the company's website at www.immunovant.com. Immunovant specializes in treating autoimmune diseases and is known for its innovative therapies, including the investigational compound batoclimab.
Immunovant is hosting a virtual R&D event on March 30, 2022, showcasing discussions on therapies for autoimmune diseases like thyroid eye disease and myasthenia gravis. The event will feature six key opinion leaders in these fields, focusing on the treatment landscape and the potential of batoclimab (IMVT-1401) to meet patient needs. New analyses from the Phase 2b study on thyroid eye disease and a Phase 1 study on batoclimab and atorvastatin will be presented, followed by a live Q&A with company management.
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company, announced that CEO Pete Salzmann will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference from February 14-18, 2022. The chat is scheduled for February 16 at 11:20 AM ET. Investors can access the webcast via the Investor Relations section of Immunovant's website. The company focuses on developing batoclimab, a monoclonal antibody aimed at treating autoimmune diseases driven by pathogenic IgG antibodies.
Immunovant (Nasdaq: IMVT) reported its fiscal Q1 2022 results, ending December 31, 2021, with approximately $527 million in cash. R&D expenses rose to $29.8 million from $21.1 million in Q1 2021, driven by cross-indication clinical studies and personnel costs. General and administrative expenses increased to $11.5 million from $10.5 million. The net loss widened to $41.4 million ($0.36 per share), compared to $31.8 million ($0.32 per share) a year earlier. The nine-month net loss reached $109.6 million.
Immunovant has appointed Mark Levine as Chief Legal Officer, bringing over 20 years of legal experience in biopharmaceuticals. His expertise includes overseeing mergers and guiding regulatory compliance. As the company accelerates the development of its drug batoclimab, Levine's addition is expected to enhance strategic capabilities. Notably, Immunovant plans to initiate three pivotal trials for batoclimab in 2022, focusing on myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic anemia, among others.